NASDAQ : NBIX

Neurocrine Biosciences, Inc. — Key statistics

Healthcare · Drug Manufacturers - Specialty & Generic · United States

Last price 146.1 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 14.85B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Key statistics

Valuation

Measure	Value
Market Cap	14.85B
Enterprise Value	14.92B

Dates

Measure	Value
Earnings Date	Nov 2, 2026
Ex-Dividend Date	n/a

Shares

Measure	Value
Current Share Class	101.65M
Shares Outstanding	101.65M
Shares Change (YoY)	+0.78%
Shares Change (QoQ)	+0.77%
Owned by Insiders (%)	1.20%
Owned by Institutions (%)	102.76%
Float	100.35M

Ratios

Measure	Value
PE Ratio	21.41
Forward PE	12.87
PS Ratio	4.40
Forward PS	3.42
PB Ratio	4.02
P/TBV Ratio	15.36
P/FCF Ratio	17.06
P/OCF Ratio	16.54
PEG Ratio	0.32

Evratios

Measure	Value
EV / Earnings	21.15
EV / Sales	4.42
EV / EBITDA	16.34
EV / EBIT	17.23
EV / FCF	17.14

Financialposition

Measure	Value
Current Ratio	1.87
Quick Ratio	1.46
Debt / Equity	0.12
Debt / EBITDA	0.47
Debt / FCF	0.53
Interest Coverage	298.62

Financialefficiency

Measure	Value
Return on Equity (ROE)	22.09%
Return on Assets (ROA)	11.70%
Return on Invested Capital (ROIC)	20.56%
Return on Capital Employed (ROCE)	19.31%
Weighted Average Cost of Capital (WACC)	6.27%
Revenue Per Employee	$1.35M
Profits Per Employee	$282,200
Employee Count	2,500
Asset Turnover	0.73
Inventory Turnover	14.88

Taxes

Measure	Value
Income Tax	234.70M
Effective Tax Rate	24.96%

Stockprice

Measure	Value
Beta (5Y)	0.40
52-Week Price Change	+5.85%
50-Day Moving Average	146.63
200-Day Moving Average	147.38
Relative Strength Index (RSI)	55.46
Average Volume (20 Days)	1,219,157

Shortselling

Measure	Value
Short Interest	6.45M
Short Previous Month	5.85M
Short % of Shares Out	6.34%
Short % of Float	6.42%
Short Ratio (days to cover)	4.41

Incomestatement

Measure	Value
Revenue	3.37B
Gross Profit	2.18B
Operating Income	866.00M
Pretax Income	940.20M
Net Income	705.50M
EBITDA	913.30M
EBIT	866.00M
Earnings Per Share (EPS)	$6.82

Balancesheet

Measure	Value
Cash & Cash Equivalents	389.80M
Total Debt	461.60M
Net Cash	-71.80M
Net Cash Per Share	-$0.71
Equity (Book Value)	3.69B
Book Value Per Share	36.35
Working Capital	763.00M

Cashflow

Measure	Value
Operating Cash Flow	898.10M
Capital Expenditures	-27.70M
Depreciation & Amortization	47.30M
Net Borrowing	n/a
Free Cash Flow	870.40M
FCF Per Share	$8.56

Margins

Measure	Value
Gross Margin	64.48%
Operating Margin	25.67%
Pretax Margin	27.87%
Profit Margin	20.91%
EBITDA Margin	27.07%
EBIT Margin	25.67%
FCF Margin	25.80%

Dividends

Measure	Value
Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
FCF Payout Ratio	n/a
Buyback Yield	-0.78%
Shareholder Yield	-0.78%
Earnings Yield	4.67%
FCF Yield	5.86%

Analystforecasts

Measure	Value
Price Target	$206.22
Price Target Difference	41.15%
Analyst Consensus	Strong Buy
Analyst Count	29
Revenue Growth Forecast (3Y)	20.89%
EPS Growth Forecast (3Y)	32.91%

Stocksplits

Measure	Value
Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Measure	Value
Altman Z-Score	6.57
Piotroski F-Score	6

Fairvalue

Measure	Value
Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside